Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Field HEOR team will work collaboratively with in-house teams to generate evidence-based solutions to optimize patient access while also integrating with in-field access teams to effectively translate HEOR evidence to targeted payer customers. We are currently hiring four Senior Directors that will report to the Executive Director of HEOR Payer and HTA Strategy. These are unique roles as they will not only be responsible for strategy development and executing HEOR research across Rev Meds portfolio but will also be embedded into field payer / access teams. The Senior Director, Field HEOR will be accountable for working collaboratively with the HEOR TA lead conducting customer centric research across an assets lifecycle that demonstrates the value of Rev Med’s products. The customer facing responsibilities of this role include partnering with field access teams, translating HEOR evidence to population level decision makers, cultivating research partnerships, developing relationships with external HEOR researchers and establishing evidentiary solutions to solve access challenges. The Senior Director of Field HEOR is a critical member of the HEOR organization to direct evidentiary strategies that are customer and patient centric. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in Oncology.